A Phase 1b/2 study with AMG 102 in Prostate Cancer

• Research type

  Research Study

• Full title

  A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer

• IRAS ID

  15861

• Sponsor organisation

  Amgen Limited

• Eudract number

  2008-004355-30

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  N/A

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  09/H0305/67

• Date of REC Opinion

  24 Aug 2009

• REC opinion

  Further Information Favourable Opinion